



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Promestriene

Cat. No.:	HY-108293
CAS No.:	39219-28-8
Molecular Formula:	C ₂₂ H ₃₂ O ₂
Molecular Weight:	328.49
Target:	Estrogen Receptor/ERR
Pathway:	Vitamin D Related/Nuclear Receptor
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 20 mg/mL (60.88 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		3.0442 mL	15.2212 mL	30.4423 mL
		5 mM		0.6088 mL	3.0442 mL	6.0885 mL
		10 mM		0.3044 mL	1.5221 mL	3.0442 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2 mg/mL (6.09 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2 mg/mL (6.09 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Promestriene is a synthetic diethyl-ether of estradiol and a locally effective estrogen. Promestriene has an efficient action on vaginal atrophy while it is minimally absorbed ^{[1][2]} .
In Vitro	Promestriene is an analogue of oestradiol which is minimally absorbed and devoid of systemic effects when administered intravaginally, either as gynecological cream or capsules ^[2] . Topical Promestriene is minimally absorbed with chronic use and has been reported to significantly improve the symptoms of vaginal atrophy ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Isabel Santos, et al. Urogenital Disorders Associated With Oestrogen Deficiency: The Role of Promestriene as Topical Oestrogen Therapy. *Gynecol Endocrinol*. 2010 Sep;26(9):644-51.
- [2]. Lino Del Pup, et al. Promestriene, a Specific Topic Estrogen. Review of 40 Years of Vaginal Atrophy Treatment: Is It Safe Even in Cancer Patients. *Anticancer Drugs*. 2013 Nov;24(10):989-98.
- [3]. AJO Almodovar, et al. Abstract P5-05-07: Promestriene effects on estrogen-sensitive breast cancer cell proliferation in vitro. *Cancer Res* 2013;73(24 Suppl): Abstract nr P5-05-07.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA